Accelerator mass spectrometry (AMS), in conjunction with LC, has been applied as a quantitative tool which enables innovative study designs employing 14C enriched analytes. The use of the 14C-label permits the determination of absolute bioavailability, clearance and volume of distribution by IV administration of the 14C analyte concomitant with extravascular pharmacological dose of unlabelled compound.
This poster describes the progress of an investigation to compare quantitation of data with reference to a calibration curve compared with the methodology reported previously by Lappin et al (Bioanalysis, Feb 2011, 3 (4), 407-410). This investigation highlighted how with an extension of this approach the data generated can mirror those obtained with weighted linear regression. Further this approaches provides the generation of data in a manner orthogonal to that using calibration, which offers very useful assay diagnostics.
GSK publish on the use of AMS to determine the absolute bioavailability of dabrafenib, a BRAF inhibitor, in patients
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.